MAX S WICHA, MD
Osteopathic Medicine in Ann Arbor, MI
License number
Michigan 4301042541
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Michigan 4301042541
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1500 Floor Cancer & Geriatrics Ctr, Ann Arbor, MI 48109
Phone
(734) 936-6000
(734) 936-2047
(734) 936-2047
Personal information
See more information about MAX S WICHA at radaris.comName
Address
Phone
2865 Parkridge Dr, Ann Arbor, MI 48103
1500 Medical Center Dr, Ann Arbor, MI 48109
2685 Parkridge Dr, Ann Arbor, MI 48103
2865 Parkridge Dr, Ann Arbor, MI 48103
Professional information
Dr. Max S Wicha, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Univers Of Mich Comp Canc Ctr
1500 E Medical Center Dr, Ann Arbor 48109
(734) 647-8901 (Phone)
1500 E Medical Center Dr, Ann Arbor 48109
(734) 647-8901 (Phone)
Certifications:
Internal Medicine, 1977, Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Univers Of Mich Comp Canc Ctr
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
Stanford University
Graduated: 1974
U Chicago Hosps
National Institutes Of Health Clinical Center
Stanford University
Graduated: 1974
U Chicago Hosps
National Institutes Of Health Clinical Center
Prospective Identification And Characterization Of Breast Cancer Stem Cells
US Patent:
2009000, Jan 1, 2009
Filed:
Jan 9, 2007
Appl. No.:
11/651214
Inventors:
Michael F. Clarke - Palo Alto CA, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - La Jolla CA, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - La Jolla CA, US
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241721
Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Prospective Identification And Characterization Of Breast Cancer Stem Cells
US Patent:
2005008, Apr 28, 2005
Filed:
Dec 6, 2002
Appl. No.:
10/497791
Inventors:
Michael Clarke - Ann Arbor MI, US
Max Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Cambridge MA, US
Max Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Cambridge MA, US
International Classification:
A61K039/395, A61K038/17
US Classification:
424143100, 514002000
Abstract:
Human breast tumors contain hetrogeneous cancer cells. using an animal xenograft model in which human breast cancer cells were grown in immunocompromised mice we found that only a small minority of breast cancer cells had capacity to form new tumors. The ability to form new tumors was not a slochastic property, rather certain populations of cancer cells were depleted for the ability to form new tumors, while other populations were enriched for the ability to form new tumors. Tumorigenic cells could be distinguished from non-tumorigenic cancer cells based on surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD44CD24LINEAGE A few as 100 cells from this population were able to form tumors the animal xenograft model, while tens of thousands of cells from non-tumorigenic populations failed to form tumors. The tumorigenic cells could be serially passaged, each time generating new tumors containing and expanded numbers of CD44Lineage tumorigenic cells as well as phenotypically mixed populations of non-tumorigenic cancer cells. This is reminiscent of the ability of normal stem cells to self-renew and differentiate. The expression of potential therapeutic targets also differed between the tumorigenic and non-tumorigenic populations. Notch activation promoted the survival of the tumorigenic cells, and a blocking antibody against Notch 4 induced tumorigenic breast cancer cells to undergo apoptosis.
Max Wicha, Ann Arbor MI
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Va Ann Arbor Healthcare System
2215 Fuller Rd, Ann Arbor, MI 48105 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109
2215 Fuller Rd, Ann Arbor, MI 48105 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
Stanford University (1974)
Compositions And Methods For Treating And Diagnosing Pancreatic Cancer
US Patent:
2008026, Oct 23, 2008
Filed:
Jan 24, 2008
Appl. No.:
12/019339
Inventors:
Max S. Wicha - Ann Arbor MI, US
Diane M. Simeone - Ann Arbor MI, US
Michael F. Clarke - Menlo Park CA, US
Diane M. Simeone - Ann Arbor MI, US
Michael F. Clarke - Menlo Park CA, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
G01N 33/574, C12N 5/06
US Classification:
435 723, 435366, 435371, 435378
Abstract:
The present invention relates to the field of oncology and provides novel compositions and methods for diagnosing and treating pancreatic cancer. In particular, the present invention provides pancreatic cancer stem cells useful for the study, diagnosis, and treatment of solid tumors.
Aldh1 As A Cancer Stem Cell Marker
US Patent:
2008018, Aug 7, 2008
Filed:
Sep 24, 2007
Appl. No.:
11/859901
Inventors:
Max S. Wicha - Ann Arbor MI, US
Gabriela Dontu - Ann Arbor MI, US
Christophe Ginestier - Ann Arbor MI, US
Emmanuelle Charafe-Jauffret - Marsielle, FR
Suling Liu - Ann Arbor MI, US
Gabriela Dontu - Ann Arbor MI, US
Christophe Ginestier - Ann Arbor MI, US
Emmanuelle Charafe-Jauffret - Marsielle, FR
Suling Liu - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
G01N 33/53, C12N 5/00
US Classification:
435 74, 435325
Abstract:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
Isolation And Use Of Solid Tumor Stem Cells
US Patent:
2006005, Mar 9, 2006
Filed:
Jun 10, 2005
Appl. No.:
11/150073
Inventors:
Michael Clarke - Ann Arbor MI, US
Sean Morrison - Ann Arbor MI, US
Max Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Cambridge MI, US
Sean Morrison - Ann Arbor MI, US
Max Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Cambridge MI, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12N 5/08
US Classification:
424093700, 435374000
Abstract:
A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Isolation And Use Of Solid Tumor Stem Cells
US Patent:
7115360, Oct 3, 2006
Filed:
Aug 2, 2001
Appl. No.:
10/343692
Inventors:
Michael F. Clarke - Ann Arbor MI, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad al-Hajj - La Jolla CA, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad al-Hajj - La Jolla CA, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/00, C12N 5/00
US Classification:
435 4, 435325, 435366, 435371, 435374
Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell.
Isolation And Use Of Solid Tumor Stem Cells
US Patent:
2008019, Aug 14, 2008
Filed:
Apr 20, 2007
Appl. No.:
11/788489
Inventors:
Michael F. Clarke - Palo Alto CA, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - La Jolla CA, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - La Jolla CA, US
International Classification:
C12N 5/06
US Classification:
435377, 435375
Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell.We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells.We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
Isolation And Use Of Solid Tumor Stem Cells
US Patent:
7713710, May 11, 2010
Filed:
May 24, 2007
Appl. No.:
11/753191
Inventors:
Michael F. Clarke - Ann Arbor MI, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Ann Arbor MI, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.